Aspen Neuroscience is expected to list on Nasdaq under the symbol ASPE on 2026-10-30, but the price range was not disclosed before pricing. The company is a clinical-stage Parkinson’s disease biotech, so the bull case is a large unmet-need market and the bear case is heavy clinical and regulatory risk.
Aspen Neuroscience is expected to list on Nasdaq under the symbol ASPE on 2026-10-30, but the price range was not disclosed before pricing. The company is a clinical-stage Parkinson’s disease biotech, so the bull case is a large unmet-need market and the bear case is heavy clinical and regulatory risk.
Quick Facts
Expected listing date: October 30, 2026
Exchange: NASDAQ
Proposed symbol: ASPE
Shares offered: 9.38M shares
Implied market cap: $425M
Status: Priced
Company Overview
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company focused on autologous induced-pluripotent stem cell, or iPSC, therapies for neurodegenerative disease, starting with Parkinson’s disease. Its lead candidate is sasineprocel, a single-dose autologous iPSC-based cell therapy designed to replace lost dopaminergic neurons with dopaminergic neuron precursor cells. The company says sasineprocel is being evaluated in its ongoing Phase 1/2a ASPIRO trial.
Aspen was incorporated in Delaware on May 18, 2018 and is headquartered in San Diego, California. It is still pre-commercial, with no product revenue disclosed and no approved therapies. The broader market it is targeting is large and difficult: Parkinson’s disease is the second most common neurodegenerative condition after Alzheimer’s, prevalence has doubled globally over the past 25 years, and current standard-of-care treatments do not halt disease progression. That makes the opportunity compelling, but also highly competitive and scientifically demanding, with many programs competing for a disease-modifying angle in CNS and cell therapy.
Why They're Going Public
Aspen says it intends to use IPO proceeds, together with existing cash, to fund clinical development of sasineprocel, including the ongoing Phase 1/2a ASPIRO trial and the initiation of a Phase 3 trial in sporadic and genetic Parkinson’s disease. The company also plans to direct capital toward research and development for other product candidates, plus working capital and general corporate purposes.
Going public gives Aspen a larger capital base for a long development runway. The company priced 9,375,000 shares at $15.00 each, implying gross proceeds of about $140.6 million before fees, which should help support the next clinical steps and manufacturing scale-up needs as it tries to move from early human data toward pivotal testing.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Aspen remains a pre-revenue biotech. The company has not generated any revenue from product sales to date, and the filing does not disclose collaboration revenue in the summary financial tables. Losses widened as development spending increased: net loss was $48.6 million in 2024 and $62.1 million in 2025, then $36.5 million in the first half of 2026 versus $31.8 million in the first half of 2025.
Research and development expense is the main cost driver. R&D was $35.6 million in 2024, $41.8 million in 2025, and $28.5 million in the first six months of 2026 versus $20.8 million in the same period of 2025. Net cash used in operating activities was $52.8 million in 2025 and $34.5 million in the first half of 2026. Cash and cash equivalents were $82.1 million at December 31, 2025 and $21.3 million at June 30, 2026, while the company also stated it had $72.4 million of cash, cash equivalents and marketable securities at June 30, 2026.
Risk Factors
The biggest risk is clinical: sasineprocel may fail to show adequate safety or efficacy, and the company has no approved products. Aspen’s future depends on moving a complex cell therapy through clinical development and then through FDA review, which requires successful IND, clinical trials, and BLA approval. If the data disappoint, the equity story weakens quickly because there is no commercial revenue to cushion the downside.
Execution risk is also high on the manufacturing side. The company says it does not currently have redundant supply or a second source for all required materials and components, which matters for a personalized autologous therapy. Investors should also watch dilution and lockup overhang: directors, officers, and substantially all securityholders agreed to a 180-day lockup, and up to 19,703,600 shares could become eligible for sale after expiration, including 12,762,164 shares held by directors, officers, and affiliates. The stock may also be volatile because there was no public market before the IPO.
Comparable Public Companies
Closest public comps are other clinical-stage cell therapy and regenerative medicine names, including Bluebird Bio (BLUE), Fate Therapeutics (FATE), and Sana Biotechnology (SANA). Those companies are useful reference points because they are also trying to turn advanced cell therapy science into commercial products, but Aspen is earlier in its path because it is still centered on a single lead Parkinson’s program and has no product revenue.
A second peer set includes Beam Therapeutics (BEAM) and Editas Medicine (EDIT), which are not direct Parkinson’s comparables but help frame how the market prices platform-heavy, pre-commercial genetic medicine stories. Relative to those names, Aspen’s story is narrower and more disease-specific, which can help with narrative clarity but also concentrates risk in one lead asset and one indication.
The sector backdrop is mixed rather than euphoric. Many pre-commercial biotech stocks have remained highly selective, with investors rewarding clinical catalysts and punishing dilution or weak data. In that environment, Aspen’s pricing at $15.00 per share and implied market cap of about $424.5 million puts it in the small-cap biotech bucket where valuation tends to hinge more on trial execution than on near-term fundamentals.
Verdict
Aspen’s IPO is a clean story for investors who want exposure to a potentially first-in-class Parkinson’s disease cell therapy, but the setup is still very much about proof rather than proof of business. The company priced at $15.00 per share for 9,375,000 shares, giving it an implied market cap of about $424.5 million. That leaves room for upside if ASPIRO continues to generate encouraging data and the company can advance toward Phase 3, but it also leaves little margin for disappointment because there is no revenue base and the path to approval is long.
The timing angle matters: this is a disease-area narrative with real unmet need, and Parkinson’s remains one of the more compelling secular opportunities in CNS because current therapies do not stop progression. That makes Aspen noteworthy right now as a rare public-market bet on autologous iPSC therapy in Parkinson’s. Shareholders should watch the next clinical readouts, the company’s ability to fund the Phase 3 transition, and how the stock trades once lockup risk and post-IPO volatility settle in.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
